In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Akebia Therapeutics (AKBA), with a price target of $16. The company’s shares opened today at $9.
Yang wrote:
“We see the results as providing positive read-through ahead of the U.S./ EU Phase III Study results anticipated in early-and mid-2020.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.1% and a 50.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
The the analyst consensus on Akebia Therapeutics is currently a Moderate Buy rating.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.04 and a one-year low of $5.20. Currently, Akebia Therapeutics has an average volume of 1.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders.
